logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Epilepsy Complex Partial

    FiltersReset Filters
    13 results

    • depakote

      (Divalproex Sodium)
      AbbVie Inc.
      Usage: Depakote ER is indicated for treating acute manic or mixed episodes of bipolar disorder, complex partial seizures, simple and complex absence seizures, and for migraine prophylaxis. It is not effective for acute migraine treatment. Considerations regarding pregnancy and potential risks are crucial for women of childbearing potential.

    • divalproex sodium

      (Divalproex Sodium)
      Aurobindo Pharma Limited
      Usage: Divalproex sodium delayed-release tablets are indicated for treating manic episodes in bipolar disorder, as well as for monotherapy and adjunctive therapy in epilepsy (complex partial and absence seizures). They are also used for migraine prophylaxis but not for acute treatment. Not suitable for pregnant women or those planning pregnancy.

    • divalproex sodium

      (divalproex sodium)
      Bionpharma Inc.
      Usage: Divalproex sodium is indicated for treating manic episodes in bipolar disorder, managing complex partial and absence seizures in epilepsy, and for migraine prophylaxis. Long-term efficacy in mania is not established. Use is contraindicated in pregnant women and those of childbearing potential not on effective contraception due to risks of fetal harm.

    • phenytoin

      (Phenytoin)
      Rising Pharma Holdings, Inc.
      Usage: Phenytoin chewable tablets are indicated for treating generalized tonic-clonic and complex partial seizures, as well as for preventing and treating seizures during or after neurosurgery.

    • primidone

      (Primidone)
      Advagen Pharma Limited
      Usage: Primidone is indicated for controlling grand mal, psychomotor, and focal epileptic seizures, either alone or in combination with other anticonvulsants. It is also effective for grand mal seizures that do not respond to other treatments.

    • sabril

      (vigabatrin)
      Lundbeck Pharmaceuticals LLC
      Usage: SABRIL is indicated as adjunctive therapy for refractory complex partial seizures in patients aged 2 and older who have not responded to other treatments, and as monotherapy for infantile spasms in pediatric patients aged 1 month to 2 years, weighing the potential benefits against the risk of vision loss.

    • valproate sodium

      (VALPROATE SODIUM)
      Fresenius Kabi USA, LLC
      Usage: Valproate sodium injection is indicated for intravenous treatment of epilepsy, including complex partial seizures, simple and complex absence seizures, and as adjunct therapy for multiple seizure types. It is not recommended for women who are pregnant or of childbearing potential unless other treatments are ineffective.

    • valproate sodium

      (Valproate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Valproate Sodium Injection is indicated for intravenous use in patients with epilepsy, specifically for complex partial, simple and complex absence seizures. It serves as both monotherapy and adjunctive therapy. Usage is limited in women of childbearing potential or during pregnancy due to significant risks to fetal development.

    • valproate sodium

      (valproate sodium)
      Athenex Pharmaceutical Division, LLC.
      Usage: Valproate Sodium Injection is indicated for intravenous use in epilepsy, specifically for complex partial seizures and simple/complex absence seizures, both as monotherapy and adjunctive therapy. It is not recommended for pregnant women or those of childbearing potential without alternative treatment failures due to potential fetal risks.

    • valproic acid

      (valproic acid)
      Upsher-Smith Laboratories, LLC
      Usage: Valproic acid capsules are indicated for treating epilepsy, specifically as monotherapy and adjunctive therapy for complex partial seizures, simple and complex absence seizures, and multiple seizure types. Use is limited in women of childbearing potential due to risks of fetal harm and congenital malformations.